Filed March 31, 2016

Serial No. 86960150

Registered Oct. 9, 2018

Registration No. 5,577,939

Interlocutory Attorney REBECCA J STEMPIEN_COYLE

Class Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; sanitary preparations for medical purposes; vaccines; pharmaceutical and medicinal preparations and substances, namely, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; diagnostic reagents and substances, all for in vivo medical use; antibodies, and therapeutic antibodies for use as anti-lymphocytic agents for medical use; pharmaceutical preparations in the form of foams or for use in producing foams, for sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial hemorrhages, cerebral hemorrhages, hematomas, and as antidotes; pharmaceutical preparations for the treatment of cancer; pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of hypertension; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of multiple neurodegeneration and multiple sclerosis; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of immune disorders namely, type 1 diabetes, psoriasis, coeliac disease and rheumatoid arthritis; pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; pharmaceutical preparations for the treatment of sepsis; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical prepraations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical or veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity, and for use in the treatment of pre-eclampsia; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity and for use in the treatment of pre-eclampsia; transarterial chemoembolization pharmaceutical preparations, vaccines and sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; beads, including microscopic radioactive beads, for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumours; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and treatment of autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents; 006; 018; 044; 046; 051; 052; 021; 023; 026; 036; 038; 026; 039; 044; 100; 101; 107; 100; 101

Case Type Trademark Service mark